Valuation: Relmada Therapeutics, Inc.

Market Cap 362M 323M 300M 273M 516M 35B 518M 3.62B 1.42B 17.84B 1.36B 1.33B 57.26B P/E 2026 *
-5.45x
P/E 2027 * -4.25x
Enterprise Value 362M 323M 300M 273M 516M 35B 518M 3.62B 1.42B 17.84B 1.36B 1.33B 57.26B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.77%
Yield 2026 *
-
Yield 2027 * -
1 day+6.94%
1 week-5.83%
Current month-10.08%
1 month-25.00%
3 months-47.11%
6 months-53.50%
Current year-29.81%
1 week 3.1
Extreme 3.1
3.54
1 month 3.1
Extreme 3.1
4.57
Current year 3.1
Extreme 3.1
8
1 year 1.8
Extreme 1.8033
8
3 years 0.24
Extreme 0.2404
8
5 years 0.24
Extreme 0.2404
38.68
10 years 0.24
Extreme 0.2404
54
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 27/10/2020
Chief Executive Officer 65 01/04/2012
Director of Finance/CFO 61 09/01/2020
Director TitleAgeSince
Director/Board Member 65 01/04/2012
Chairman 79 15/06/2017
Director/Board Member 68 12/11/2015
Date Insider Type Main position Quantity % Market Cap. Importance
9/10/26 A Buy

Chief Financial Officer

79,800 0.0748%
9/10/26 A Buy

Chief Executive Officer

100,000 0.0937%
12/12/25 A Buy

Chief Financial Officer

839,665 1.1450%
Change 5-day change 1-year change 3-year change Capi.($)
+6.94%-5.83%+66.18%-3.97% 362M
-2.59%-5.70%+50.69%+79.01% 70.61B
+3.23%-10.67%+6.27%+53.48% 51.01B
+1.56%+1.17%+8.49%+32.39% 48.1B
+0.39%+0.65%+31.14%+27.04% 42.78B
+0.87%-8.17%+293.37%+643.87% 40.67B
+1.24%-1.01%+10.74%+94.55% 40.3B
-2.13%-1.64%+8.63%+46.15% 30.59B
-0.46%-1.28%+42.23%+14.70% 28.16B
+5.32%+0.06%-5.00%-12.60% 24.36B
Average +1.44%-2.97%+51.27%+97.46% 37.69B
Weighted average by Cap. +0.56%-2.95%+51.36%+112.85%

Financials

2026 *2027 *
Net sales - -
Net income -66.35M -59.26M -55.12M -50.14M -94.67M -6.42B -95.08M -663M -260M -3.27B -249M -244M -10.51B -94.92M -84.77M -78.86M -71.73M -135M -9.19B -136M -949M -372M -4.68B -356M -349M -15.03B
Net Debt - -
Projected Income Statement - Annual - Relmada Therapeutics, Inc.
Logo Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Employees
17
Date Price Change Volume
09/10/26 $3.390 +6.94% 1,730,502
08/10/26 $3.170 -2.46% 1,886,414
07/10/26 $3.250 -0.91% 1,497,317
06/10/26 $3.280 -5.75% 1,735,689
05/10/26 $3.480 -3.33% 1,282,546
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Relmada Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.390USD
Average target price
10.75USD
Spread / Average Target
+217.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Relmada Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RLMD Stock